Erasca to Present at Upcoming Conferences in February
Rhea-AI Summary
Erasca (Nasdaq: ERAS) announced management will present and hold one-on-one investor meetings at two February 2026 conferences: Guggenheim Emerging Outlook: Biotech Summit (Feb 11-12) and Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 25-26).
Fireside chat times: Feb 12 at 1:00 PM ET (Guggenheim) and Feb 26 at 11:20 AM ET (Oppenheimer). Live audio webcasts and archived replays will be available at Erasca.com/events for 30 days following each webcast.
Positive
- None.
Negative
- None.
News Market Reaction – ERAS
On the day this news was published, ERAS gained 5.69%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.5% during that session. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $202M to the company's valuation, bringing the market cap to $3.75B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ERAS gained 6.19% while peers showed mixed moves: ALMS -2.7%, ZVRA -2.83%, ITOS +0.1%, OLMA +0.5%, PRTA +1.37%. This points to a stock-specific move rather than a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 23 | Equity offering close | Negative | -3.5% | Closed upsized common stock offering at $10.00 for $258.8M gross. |
| Jan 21 | Equity offering pricing | Negative | +2.5% | Priced upsized 22,500,000-share offering at $10.00 per share. |
| Jan 20 | Proposed equity offering | Negative | +2.0% | Proposed $150.0M common stock offering under effective shelf. |
| Jan 12 | Early clinical data | Positive | -7.8% | Reported early Phase 1 responses for ERAS-0015 with favorable safety profile. |
| Jan 06 | Conference presentation | Neutral | +4.0% | Announced J.P. Morgan Healthcare Conference presentation with webcast and replay. |
Recent history shows frequent divergences: positive clinical and neutral conference updates sometimes saw negative or outsized positive moves, and equity offerings produced mixed reactions rather than consistent selloffs.
Over the past month, ERAS issued several equity offerings and liquidity updates, including a proposed $150.0M offering on Jan 20, upsized pricing on Jan 21, and closing of 25,875,000 shares on Jan 23. Clinical data for ERAS-0015 on Jan 12 and a J.P. Morgan conference appearance on Jan 6 also shaped sentiment. Today’s conference participation news fits the pattern of communications aimed at investor engagement alongside ongoing development and financing activities.
Regulatory & Risk Context
An effective S-3 shelf filed on Aug 12, 2025 allows ERAS to issue up to $500,000,000 in various securities, including up to $200,000,000 of common stock via an at-the-market program with Jefferies LLC. Two recent 424B5 takedowns in January 2026 indicate active use of this financing flexibility.
Market Pulse Summary
The stock moved +5.7% in the session following this news. A strong positive reaction aligns with ERAS trading near its 52-week high at $11.24, even though this announcement only confirms participation in investor conferences and webcasts. Historical data show mixed reactions to news, including divergences on offerings and clinical updates, so a sharp move on routine conference news could reflect positioning, prior financings, or momentum rather than a change in fundamentals.
AI-generated analysis. Not financial advice.
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in February 2026 and will also participate in one-on-one investor meetings at each of these conferences.
Guggenheim Emerging Outlook: Biotech Summit 2026 (February 11-12, 2026)
Location: New York, NY
Format: Fireside Chat
Date and Time: Thursday, February 12, 1:00 pm Eastern Time
Oppenheimer 36th Annual Healthcare Life Sciences Conference (February 25-26, 2026)
Location: Virtual
Format: Fireside Chat
Date and Time: Thursday, February 26, 11:20 am Eastern Time
A live audio webcast of the events will be available online at Erasca.com/events. An archived replay of the events will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
When will Erasca (ERAS) present at the Guggenheim Emerging Outlook: Biotech Summit in February 2026?
What is the schedule for Erasca (ERAS) at the Oppenheimer 36th Annual Healthcare Life Sciences Conference in February 2026?
How can investors access Erasca (ERAS) webcasts for the February 2026 conferences?
Will Erasca (ERAS) hold one-on-one investor meetings at the February 2026 conferences?
Where are the February 2026 Erasca (ERAS) events located and what formats will they use?
